Previous 10 | Next 10 |
Results from UB-312’s Part A first-in-human trials published in Movement Disorders DALLAS, April 28, 2022 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX ), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today announced it has co...
The Coalition for Epidemic Preparedness Innovations (CEPI) will co-fund Vaxxinity's (NASDAQ:VAXX) global Phase 3 trial of COVID-19 vaccine candidate, UB-612, as a heterologous – or mix-and-match – booster dose. CEPI would provide up to $9.25M to fund the late...
OSLO, Norway and DALLAS, April 06, 2022 (GLOBE NEWSWIRE) -- The Coalition for Epidemic Preparedness Innovations (CEPI) and Vaxxinity, Inc. (Nasdaq: VAXX), a US company pioneering the development of a new class of immunotherapeutic vaccines, today announced that they will co-fund the ongoing...
Vaxxinity (NASDAQ:VAXX) began dosing participants in a phase 3 trial evaluating its COVID-19 booster candidate, UB-612. The company said the trial was enrolling participants 16 years and older who have completed a two-dose primary immunization regimen with an mRNA (Pfizer and B...
Pivotal Phase 3 head-to-head study will evaluate non-inferiority of heterologous booster candidate UB-612 against authorized mRNA, adenovirus vector and inactivated virus COVID-19 vaccines Agreement reached with global regulators on trial design and data package required to ...
Vaxxinity press release (NASDAQ:VAXX): Q4 GAAP EPS of -$0.48. Q4 Cash cash and equivalents $144.9M For further details see: Vaxxinity GAAP EPS of -$0.48
DALLAS, March 24, 2022 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today reported financial results for the fourth quarter and full year ended December 31, 2021. “2021 was a transfor...
DALLAS, March 21, 2022 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines for chronic diseases, today announced that Peter Powchik, M.D. is joining its Board of Directors and will be retiring as Vaxxinit...
Vaxxinity (VAXX +3.0%) shares are trading higher after announcing that the company’s experimental COVID-19 vaccine UB-612 generated an antibody response three times stronger than the approved mRNA vaccines following a three-dose regimen. The protein-based vaccine candidate was also fou...
Investigator-sponsored studies show UB-612 induces high antibody activity against multiple variants, including Alpha, Beta, Delta, Gamma and Omicron, at levels similar to or higher than approved vaccines UB-612 elicits >3 times higher titers of neutralizing antibodies aga...
News, Short Squeeze, Breakout and More Instantly...
UB-312 is the first Parkinson's candidate to reduce pathology as measured by a seed amplification assay, and suggest clinical improvement on motor experiences of daily living. Data demonstrates target engagement and immunogenicity of the active immunotherapy UB-312 targeting pathological ...
BowFlex Inc. (BFXXQ) is expected to report for Q4 2024 Leafbuyer Technologies Inc (LBUY) is expected to report for Q3 2024 Pacific Booker Minerals Inc (PBMLF) is expected to report for Q1 2025 BZAM Ltd Com (BZAMF) is expected to report for Q1 2024 MJ Holdings Inc (MJNE) is expecte...
Orbital Infrastructure Group Inc. (OIGBQ) is expected to report for Q1 2024 OFS Credit Company Inc. (OCCI) is expected to report for Q2 2024 KBC Groupe NV ADR (KBCSY) is expected to report for Q1 2024 Daikin Industries Ltd ADR (DKILY) is expected to report $0.11 for Q4 2024 Invita...